Recommended Articles
Fundraising

FluoRok Raises $30M Series A to Scale HF-Free Fluorochemical Manufacturing

By Angeled · November 6, 2026 · Fundraising
FluoRok Raises $30M Series A to Scale HF-Free Fluorochemical Manufacturing
FluoRok Raises $30M Series A to Scale HF-Free Fluorochemical Manufacturing

Oxford-based fluorochemicals startup FluoRok has raised an oversubscribed $30 million (£22.8 million) Series A round, announced on November 5, 2026. The round was led by Orano Venture Fund and Supernova Invest, and the company will use the capital to scale manufacturing of fluorochemicals made without hydrogen fluoride — one of the chemical industry's most hazardous inputs.

What Are Fluorochemicals, and Why Do They Matter?

Fluorochemicals are compounds built around fluorine, one of the most reactive elements in chemistry. They appear in an enormous range of products and industries: refrigerants, pharmaceuticals, agrochemicals, lithium-ion battery electrolytes, semiconductors, and high-performance polymers. Fluorine's unusual properties — it forms exceptionally strong bonds with carbon — make fluorinated molecules stable, resistant, and useful in ways few substitutes can match.

That usefulness comes with a manufacturing problem. The conventional route to making fluorochemicals runs through hydrogen fluoride (HF), a corrosive and highly toxic gas. HF is dangerous to handle, requires specialised equipment and safety systems, and its use creates significant regulatory and environmental burdens for producers. Any process that can make fluorochemicals without HF is therefore valuable on safety, cost, and regulatory grounds alike.

What FluoRok Does Differently

FluoRok, spun out of the University of Oxford, has developed a process for producing fluorochemicals that eliminates hydrogen fluoride from the manufacturing chain. By removing the most hazardous step, the company aims to make fluorochemical production safer, cleaner, and ultimately cheaper at scale — while still delivering the fluorinated compounds that downstream industries depend on.

The oversubscribed nature of the round is notable. In venture financing, "oversubscribed" means investor demand exceeded the amount the company set out to raise. For a deep-tech chemicals company, that signals strong conviction from investors who understand both the science and the size of the end markets.

The Investors

The round was led by Orano Venture Fund and Supernova Invest. Orano is a major French nuclear materials company, and its venture arm invests in technologies adjacent to its industrial expertise — including advanced materials and chemistry. Supernova Invest is a French venture firm with a deep-tech focus. The pairing of a strategic industrial investor with a specialist deep-tech fund is a common pattern in hard-tech financings, where technical diligence matters as much as financial analysis.

Why Fluorochemicals Are Strategic

Fluorochemicals sit at the intersection of several strategic supply chains. Battery electrolytes for electric vehicles depend on fluorinated salts. Semiconductors require fluorinated gases and materials. Pharmaceuticals rely on fluorination to tune how drugs behave in the body — a significant share of modern medicines contains at least one fluorine atom. Agrochemicals use fluorine to improve the stability and effectiveness of crop-protection products.

That breadth means a safer, cheaper way to make fluorochemicals has many potential customers across many sectors. It also means the technology touches on supply-chain resilience: much of the world's fluorochemical production is concentrated in a small number of countries, and Western governments have grown increasingly focused on securing domestic supply of critical chemicals and materials.

The Scale-Up Challenge

For FluoRok, the central challenge now is the one every chemicals startup faces: moving from laboratory and pilot-scale production to commercial manufacturing. Chemical processes that work in a flask do not automatically work in a plant. Scaling requires engineering, safety certification, customer qualification — downstream buyers must test and approve new materials before they can use them — and significant capital expenditure.

The $30 million Series A is sized for that transition. It funds the manufacturing scale-up, the hiring of process engineers and commercial staff, and the customer qualification programmes that turn a proven process into a revenue-generating business.

Why It Matters for Founders and Investors

FluoRok's raise illustrates a durable lesson for deep-tech founders: solving a safety or regulatory problem inside a large, established industry can be as valuable as creating a new market. The company did not need to convince anyone that fluorochemicals are useful — that demand already exists. It needed to show that the hazardous step in making them can be removed. That framing — same product, safer process — lowers the adoption barrier, because customers do not have to change what they buy, only where it comes from.

For investors, the round is another data point in the steady flow of capital into industrial deep tech: chemistry, materials, and manufacturing processes that make existing industries cleaner and safer. These companies take longer to scale than software, but their moats — protected processes, qualified customers, and capital-intensive plants — are correspondingly harder to replicate.

Angeled.com connects founders with investors.

Read Next